NeuroMab™ Anti-ERBB2 BBB Shuttle Antibody,Clone NR3714P

Figure 1 shows the effect of anti-ErbB2 monoclonal antibodies 2C4 and 7F3 on the activation of rHRGβ1 in MCF7 cells.

Figure 2A shows dose-response curves of 2C4 or 7F3 inhibition of stimulation of HRG tyrosine phosphorylation.

Figure 2 depicts the inhibition of specific125I-labeled rHRGβ1177-244 binding to a panel of human tumor cell lines by anti-ErbB2 monoclonal antibodies 2C4 or 7F3.

Figure 3 shows the effects of monoclonal antibodies 2C4 and 4D5 on the proliferation of MDA-MB-175 cells.

Figure 4 shows heregulin (HRG)-dependent binding of ErbB2 to ErbB3 in MCF7 cells expressing low/normal levels of ErbB2 (Panel A) and SK-BR-3 by mAb 2C4, HERCEPTIN® antibody, or anti-EGFR antibody Effects on cells expressing high levels of ErbB2 (Panel B).

Figure 5 compares the activity of intact mouse monoclonal antibody 2C4 (mu 2C4) and chimeric 2C4 Fab fragments.

Figure 6 shows the binding of chimeric Fab 2C4 (Fab.v1 ) and several humanized 2C4 variants to the ErbB2 extracellular domain (ECD) as determined by ELISA.

Figure 7 is a bar graph showing the effect of anti-ErbB2 antibodies (alone or in combination) on Calu3 lung adenocarcinoma xenografts (3+ErbB2 overexpressing). Note Stop treatment on day 24.

Figure 8 depicts the effect of recombinant humanized monoclonal antibody 2C4 (rhuMAb 2C4) or Herceptin on the growth of MDA-175 cells as assessed in the Alamar Blue assay.

Figure 9 shows the efficacy of rhuMAb 2C4 against MCF7 xenografts